Ranbaxy opts not to pursue sales of generic Clarinex
MUMBAI, India Ranbaxy Laboratories has decided to drop its bid to sell generic versions of Schering-Plough allergy medicine Clarinex (desloratadine).
Schering-Plough sued a dozen generic drug companies last year to block their versions of generic Clarinex. The agreement between Ranbaxy and Schering-Plough will end if another company is successful in challenging the validity of the patent, according to court records.
This announcement comes after recent news from Merck and Schering-Plough, which plan on creating a combination drug of their respective drugs, Singulair and Claritin. Claritin generated $455 million in global sales in the first six months.
Lilly, Takeda terminate contract
JAPAN Eli Lilly Japan and Takeda Pharmaceuticals have terminated an agreement to co-develop and co-market ruboxistaurin mesylate.
Ruboxistaurin mesylate is used to treat diabetic macular edema and diabetic peripheral neuropathy. The companies said that after looking at the overall results, the trials did not meet the criteria for Phase III studies and therefore they have agreed to terminate the contract.
Patent office announces final rule on claims
WASHINGTON The U.S. Patent and Trademark Office has issued a new rule that will change how many claims patent applications may contain, as well as how many continuing applications applicants may file.
The new rule requires that any third or subsequent continuing application that is a continuing application or a continuation-in-part application, and any second or subsequent request for continued examination in an application family, be filed to obtain consideration of an amendment, argument, or evidence, and be supported by a showing as to why the amendment, argument, or evidence sought to be entered could not have been previously submitted.
The revised rules also require an applicant to file an examination support document that covers all of the claims in an application if the application contains more than five independent claims or more than twenty-five total claims.
The new rule will go into effect on Nov. 1.